Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALC logo ALC
Upturn stock ratingUpturn stock rating
ALC logo

Alcon AG (ALC)

Upturn stock ratingUpturn stock rating
$90.05
Delayed price
Profit since last BUY-1.33%
upturn advisory
Consider higher Upturn Star rating
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/14/2025: ALC (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 13.12%
Avg. Invested days 46
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 44.54B USD
Price to earnings Ratio 38.48
1Y Target Price 99.83
Price to earnings Ratio 38.48
1Y Target Price 99.83
Volume (30-day avg) 1309653
Beta 0.76
52 Weeks Range 77.29 - 101.10
Updated Date 02/15/2025
52 Weeks Range 77.29 - 101.10
Updated Date 02/15/2025
Dividends yield (FY) 0.30%
Basic EPS (TTM) 2.34

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 11.89%
Operating Margin (TTM) 13.53%

Management Effectiveness

Return on Assets (TTM) 2.55%
Return on Equity (TTM) 5.59%

Valuation

Trailing PE 38.48
Forward PE 26.67
Enterprise Value 48209771780
Price to Sales(TTM) 4.56
Enterprise Value 48209771780
Price to Sales(TTM) 4.56
Enterprise Value to Revenue 4.94
Enterprise Value to EBITDA 38.08
Shares Outstanding 494600000
Shares Floating 493541556
Shares Outstanding 494600000
Shares Floating 493541556
Percent Insiders 0.19
Percent Institutions 68.48

AI Summary

Alcon AG: Comprehensive Overview of the US Stock

Company Profile:

History and Background: Alcon started as a division of Nestle in the 1940s and was acquired by Novartis in 1977. In 2019, Alcon was spun off from Novartis as an independent public company focused on innovative eye care solutions.

Core Business Areas: Alcon specializes in ophthalmology. Their core business areas include:

  • Surgical Solutions: Cataract, refractive, and vitreoretinal surgery products.
  • Vision Care: Contact lenses and lens care solutions.
  • Eye Care: Treatments for ocular surface diseases, glaucoma, and allergies.

Leadership and Structure: The company operates globally with headquarters in Geneva, Switzerland, and Dallas, Texas.

  • CEO: David Endicott
  • CFO: Mike Onanuga
  • Board of Directors: Diverse leadership team with expertise in medicine, business, and technology.

Top Products and Market Share:

Top Products:

  • AcrySof IQ PanOptix Trifocal IOL: Multifocal intraocular lens for the correction of presbyopia, cataracts, and astigmatism.
  • Femto LDV Z8 Femtosecond Laser: Laser for cataract surgery used to perform corneal incisions and lens fragmentation.
  • Vivity IOL: IOL for the correction of presbyopia and cataracts, offering continuous vision at all distances.
  • Dailies Total1 Multifocal: Multifocal contact lenses designed for all-day comfort and clear vision at all distances.

Market Share: Alcon holds a leading position in the global ophthalmic market:

  • Cataract surgery: 19% global market share.
  • Refractive surgery: 16% global market share.
  • Contact lenses: 18% global market share.
  • Vision Care: 24% global market share.

Total Addressable Market:

The global ophthalmic market is estimated to be valued at approximately $29.4 billion in 2023, and is projected to grow at a CAGR of 5.4% to reach $39.9 billion by 2028.

Financial Performance:

Recent Financials:

  • Revenue: Q3 2023 earnings reported $2.07 billion, an increase of 23% year-over-year.
  • Net Income: Q3 2023 earnings reported net income of $36 million.
  • Profit Margin: Operating profit margin stands at 12.7%.
  • Earnings per Share (EPS): Q3 2023 diluted EPS was $0.04.

Financial Performance Comparison:

  • Revenue increased by 17.1% in 2022 compared to 2021.
  • Profit margins have shown growth in recent years, indicating improved profitability.

Cash Flow and Balance Sheet:

  • Alcon generated $894 million in cash from operations in Q3 2023.
  • The company maintains a healthy balance sheet with a debt-to-equity ratio of 0.46.

Dividends and Shareholder Returns:

  • Dividend History: Alcon initiated a quarterly dividend of $0.10 per share in 2022.
  • Shareholder Returns: Alcon's total shareholder return over the past year is approximately 23%.

Growth Trajectory:

Historical Growth:

  • Revenue has grown at a CAGR of 8.5% over the past five years.
  • Net income has also witnessed significant growth in recent years.

Future Growth Projections:

  • Alcon's strong pipeline of innovative products, expanding presence in emerging markets, and strategic acquisitions are expected to drive future growth.

Recent Initiatives:

  • Launch of new IOL technologies like Vivity and PanOptix Trifocal.
  • Investments in digital health solutions for improved patient care.
  • Expansion into new markets like China and India.

Market Dynamics:

Industry Trends:

  • Increasing demand for ophthalmic treatments due to an aging population and rising prevalence of eye diseases.
  • Technological advancements like femtosecond lasers and digital health solutions.

Alcon's Positioning:

  • Alcon occupies a leading position in the global ophthalmic market with a strong brand portfolio and extensive R&D capabilities.

About Alcon AG

Exchange NYSE
Headquaters -
IPO Launch date 2019-04-09
CEO & Director Mr. David J. Endicott
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 25000
Full time employees 25000

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​